ArticleJournal of endocrinological investigation2026
Thyroid peroxidase antibodies and coronary artery calcification: results from the ELSA-Brasil cohort study.
Article in Journal of endocrinological investigation, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Age-dependent association of thyroid peroxidase antibodies with incident cardiovascular disease events: Insights from a longitudinal cohort study.Journal of translational autoimmunity · 2026Article
- Predictive value of thyroid autoantibodies for coronary heart disease severity in individuals with normal thyroid function based on machine learning and SHAP interpretation.Frontiers in immunology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
purposeThis study explored the association between TPOAb levels and the incidence and progression of coronary artery calcification (CAC) among participants from the Brazilian Longitudinal Study of Adult Health (ELSA-Brasil).
methodsWe included individuals with no prior cardiovascular disease who underwent two CAC measurements within the ELSA-Brasil cohort from the São Paulo Research Center. Fasting serum TPOAb levels were analyzed as continuous data, categorized in quartiles, and as detectable and positive levels. Incident CAC was defined as a baseline CAC = 0 followed by a CAC > 0 in the second measurement. CAC progression was assessed using the Hokanson method only for participants with CAC > 0 at baseline. We performed Poisson regression models with robust variance and logistic regression models using the first quartile of TPOAb as the reference.
resultsA total of 3013 individuals were included (57.2% women, age 49.3 ± 8.1 years, 55.2% white). The third (IRR = 1.38, 95% CI = 1.03-1.85) and the fourth (IRR = 1.43, 95% CI = 1.07-1.91) quartiles of TPOAb were associated with a higher risk of CAC incidence, even after adjusting for sociodemographic variables, cardiovascular risk factors, and thyroid function. These associations remained consistent in sensitivity analyses for euthyroid individuals (Q3: IRR = 1.49, 95% CI = 1.07-2.06 and Q4: IRR = 1.60, 95% CI = 1.15-2.22). Sex-stratified analyses revealed a stronger association between the fourth quartile of TPOAb and CAC incidence in men, while the third quartile was significantly associated with CAC incidence in women. There was a statistically significant association between high detectable TPOAb and CAC progression (OR = 1.50, 95% CI = 1.01-2.24).
conclusionOur findings indicate that individuals with higher levels of TPOAb were at higher risk of developing CAC over a 5-year follow-up period, suggesting an atherogenic role of TPOAb independent of thyroid function.
Indexed as
Identifiers
41251950What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.